Tests timing of heart medicines after a heart attack in adults
Compares early and late heart medicines in adults after a STEMI heart attack.
Plain-language title generated from the registry record
Registry title: STunning in Acute Myocardial Infarction - BAS
Key facts
- Where
- Gothenburg, SwedenSee the site
- Phase
- Phase 4
Where in Sweden
- Sahlgrenska University HospitalGothenburg, SwedenTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Vastra Gotaland Region
- Trial code
- NCT06562582
- Record updated
- 13 October 2026
- Original description
The objective of this trial is to examine the effect of immediate versus late administration of beta blockers, angiotensin converting enzyme inhibitors (ACEI), and sodium/glucose cotransporter 2 (SGLT2) inhibitors on echocardiographic parameters and biomarkers in subjects with ST-elevation myocardial infarction (STEMI)Read full original descriptionShow less
STunning in Acute Myocardial Infarction - Beta Blockers, Angiotensin Converting Enzyme Inhibitors and Sodium/Glucose Cotransporter 2 Inhibitors Trial A Low Intervention Clinical Tria
The objective of this trial is to examine the effect of immediate versus late administration of beta blockers, angiotensin converting enzyme inhibitors (ACEI), and sodium/glucose cotransporter 2 (SGLT2) inhibitors on echocardiographic parameters and biomarkers in subjects with ST-elevation myocardial infarction (STEMI)
Inclusion: Patients with STEMI who undergo primary PCI within 6 hours of symptom onset (Excluding prodromal symptoms); Informed consent.
Exclusion: Current treatment with any beta blocker, RAAS inhibitor or SGLT2 inhibitor; Absolute or relative contraindication to any one of the study drugs that confers a risk of patient safety if the patient participates in the trial and adheres to the protocol-specified recommendations, per the assessment of the treating physician; Pre-existing non-reversible cardiac dysfunction or heart failure; Chronic kidney disease with GFR < 25 ml/min/1.73 m2; Killip class ≥ 3; Life expectancy less than one year; Pregnancy or women of childbearing potential who is not sterilized or is not using a medically accepted form of contraception.